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Supplementary Table I. Clinical and demographic characteristics of the 21 donors from which 
we have successfully isolated and expanded APCs for this study. 
Baseline characteristics  
Male sex, n (%) 21 (100) 
Age, median [IQR] 64 [58-71]  
Hypertension, n 18 
Diabetes mellitus, n 1 
Hyperlipidaemia, n 17 
Body mass index (kg/m2), median [IQR] 32 [26-34] 
Smoking habit, n   
Previous 3 
Current 13 
Previous Myocardial Infarction 13 (54.2) 
Coronary Artery Disease, n    
                         1 vessel affected 1 
2 vessels affected 7  
3 vessels affected 13  
Angina classification (CSS score), n   
I  3 
II 4 
III 9 
IV 2 
NYHA classification, n    
I 5 
II 9 
III 1 
 
CSS (Canadian Cardiovascular Society) Functional Score 
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Supplementary Table II. Expression of surface markers in human APCs as assessed by flow cytometry   
 
Condition APC line CD90 CD73 CD140b CD44 CD34 CD105 CD31 CD45 
20% O2 
7.05.14 A 88 93 40 98 0.50 40 0.10 1.50 
28.10.14 C 86 95 42 99 0.10 77 0.10 1.30 
8.05.14 D 80 82 43 98 0.70 86 0.80 1.50 
13.10.15 E 68 98 47 97 0.60 93 0.80 0.20 
Mean  81 92 43 98 0.48 74 0.45 1.13 
SEM  5 4 1 1 0.13 12 0.20 0.31 
          
Condition APC line CD90 CD73 CD140b CD44 CD34 CD105 CD31 CD45 
2% O2 
7.05.14 A 91 90 33 99 0.60 43 0.10 0.90 
28.10.14 C 89 93 40 99 0.10 75 0.10 0.60 
8.05.14 D 70 89 50 98 0.70 84 0.70 1.50 
13.10.15 E 72 98 51 97 0.70 81 1.10 3.20 
Mean  81 93 44 98 0.53 71 0.50 1.55 
SEM  6 2 4 1 0.14 9 0.24 0.58 
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Supplementary Table III. List of the top genes modulated by hypoxia in human APCs 
 GENENAME GOCC logFC P.Value 
1.  SPAG4 spermatogenesis 3.705932 0.002295 
2.  PDK1 carbohydrate metabolic process  2.285972 3.74E-09 
3.  AHNAK nervous system development 2.067459 4.06E-07 
4.  SLC2A1 carbohydrate metabolic process  2.044775 2.80E-07 
5.  CRYM negative regulation of transcription 1.99988 0.000448 
6.  ABCD3 peroxisome organization  1.894208 2.00E-06 
7.  TERF1 G2/M transition of mitotic cell cycle   1.851164 0.00339 
8.  CCT6B protein folding  1.838416 0.006236 
9.  LEP metabolism/angiogenesis 1.819224 0.006227 
10.  OSCP1 transport 1.730382 0.003012 
11.  LHX3 regulation of transcription, DNA-dependent  1.728171 0.003373 
12.  ETNK1 phosphatidylethanolamine biosynthetic process  1.706657 1.20E-05 
13.  CTDP1 transcription   1.614284 0.008019 
14.  ENO2 carbohydrate metabolic process  1.572633 1.52E-06 
15.  OR13F1 sensory perception of smell 1.567926 0.003639 
16.  GYS1 carbohydrate metabolic process  1.534586 1.46E-05 
17.  PFKFB4 carbohydrate metabolic process  1.498669 0.007964 
18.  ALDOC response to hypoxia / apoptosis  1.489168 0.001565 
19.  ARHGEF1 Rho protein signal transduction  1.452935 0.001115 
20.  B3GALT4 protein glycosylation 1.425453 0.009055 
21.  ADSSL1 immune system process 1.414419 0.000668 
22.  CCL28 chemotaxis / immune response  1.3827 0.002895 
23.  MED23 regulation of transcription, DNA-dependent  1.38237 3.19E-05 
24.  TRIOBP barbed-end actin filament capping  modification 1.382094 5.81E-05 
25.  NXPH4 neuropeptide signaling pathway 1.37048 0.000312 
26.  CIRBP response to cold / response to UV 1.34684 5.00E-05 
27.  PTPRR in utero embryonic development tion 1.342777 0.002684 
28.  RASGRP2 regulation of cell growth / blood coagulation  1.326673 0.001154 
29.  BNIP3 response to hypoxia / apoptosis  1.325714 4.96E-06 
30.  TREM1 blood coagulation / intracellular signal transduction  1.303737 0.000893 
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31.  TCEA2 transcription elongation, DNA-dependent 1.287599 0.001964 
32.  SNTA1 muscle contraction  1.28359 0.000218 
33.  MPP2 signal transduction 1.244355 0.00699 
34.  CMTM1 chemotaxis 1.240975 0.000109 
35.  GCHFR protein complex assembly 1.21647 0.009382 
36.  LDHA pyruvate metabolic process / glycolysis 1.212298 6.16E-05 
37.  UBE3B protein ubiquitination involved  1.206514 0.001477 
38.  SLC6A8 muscle contraction / creatine metabolic process  1.204214 0.000358 
39.  HMHA1 small GTPase mediated signal transduction  1.192093 0.002556 
40.  CTNNBIP1 regulation of vascular permeability  1.182575 0.000431 
41.  PFKL carbohydrate metabolic process  1.167166 0.000667 
42.  PKP3 cell adhesion 1.161209 0.000116 
43.  FBXO2 protein ubiquitination  1.15519 0.006687 
44.  CARHSP1 intracellular signal transduction 1.152805 0.004374 
45.  SLC22A18AS biological_process 1.145768 0.000668 
46.  SLC16A3 blood coagulation / pyruvate metabolic process 1.145418 0.002141 
47.  AANAT metabolic process  1.130998 0.000191 
48.  NAT6 metabolic process 1.12475 0.002932 
49.  TPI1 carbohydrate metabolic process  1.109328 0.002914 
50.  MAST1 cytoskeleton organization / protein phosphorylation 1.105299 0.004676 
51.  GDPD5 glycerol metabolic process / lipid metabolic process  1.101075 0.00466 
52.  ADRA2C blood coagulation / energy reserve metabolic process  1.100074 0.004386 
53.  WIPF1 actin cytoskeleton organization 1.089793 0.000387 
54.  ALDH3B1 alcohol metabolic process 1.088886 0.006517 
55.  ACOT1 very long-chain fatty acid metabolic process  1.076034 0.00055 
56.  BEST4 ion transport / biological_process 1.065031 0.001634 
57.  DACH2 multicellular organismal development 1.064606 0.009908 
58.  ZNF680 regulation of transcription, DNA-dependent 1.058634 0.006961 
59.  RPP30 tRNA processing 1.058132 0.000732 
60.  SPINT2 cellular component movement 1.058098 0.004402 
61.  DYNC2LI1 multicellular organismal development  1.036759 0.002102 
62.  VEGFA angiogenesis / vasculogenesis  1.033029 0.002273 
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63.  KIAA1456 metabolic process 1.030766 0.003575 
64.  GABRA3 gamma-aminobutyric acid signaling pathway 1.021465 0.002434 
65.  SSH2 actin cytoskeleton organization  1.020271 0.000156 
66.  TLE1 signal transduction  1.018402 0.000759 
67.  PKN1 signal transduction / protein phosphorylation  1.015443 0.000155 
68.  TCF25 negative regulation of transcription  1.012701 0.000851 
69.  CCDC85B negative regulation of transcription  1.009642 0.002349 
70.  CLCN4 transport / ion transport  1.004777 0.00134 
71.  MAP1LC3A autophagic vacuole assembly / autophagy 1.003569 0.009447 
72.  RASSF7 signal transduction  1.002955 0.003799 
73.  ACSL3 fatty acid biosynthetic process  -1.00193 0.0018 
74.  SERPINH1 response to unfolded protein  -1.00277 0.000442 
75.  STRBP cellular component movement -1.00416 0.004286 
76.  MANF response to unfolded protein  biological_process -1.0043 0.000272 
77.  ZNF605 regulation of transcription, DNA-dependent -1.00537 0.001741 
78.  PMS1 ATP catabolic process  -1.0111 0.007456 
79.  CHORDC1 chaperone-mediated protein folding  -1.01377 0.009586 
80.  ZNF727 regulation of transcription, DNA-dependent -1.01591 0.003506 
81.  CTSL1 proteolysis -1.02335 0.000623 
82.  HIF1A response to hypoxia -1.02371 0.006344 
83.  DEPDC1 intracellular signal transduction  -1.02523 0.009741 
84.  CLK4 peptidyl-tyrosine phosphorylation  -1.0358 0.006531 
85.  HNRNPA2B1 nuclear mRNA splicing, via spliceosome  -1.04691 0.003321 
86.  ZNF37A transcription, DNA-dependent  -1.04826 0.004272 
87.  KHDRBS3 spermatogenesis / regulation of transcription -1.05998 0.005251 
88.  NEK10 protein phosphorylation -1.06045 0.003277 
89.  HECTD2 protein ubiquitination  -1.06068 0.003356 
90.  ZNF280D regulation of transcription -1.06133 0.007403 
91.  LUC7L negative regulation of muscle tissue development -1.06208 0.000816 
92.  TMX3 cell redox homeostasis  -1.06818 0.009781 
93.  TBCK regulation of Rab GTPase activity -1.06972 0.000216 
94.  ABCC5 transport  -1.09073 0.000218 
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95.  TRNT1 RNA processing  -1.09174 0.001091 
96.  TLR3 toll-like receptor signaling pathway  -1.09883 0.005746 
97.  NAMPT signal transduction -1.09971 0.005848 
98.  DBT metabolic process  -1.10102 0.000119 
99.  NUDT3 cell-cell signaling  -1.10319 0.000218 
100.  CCDC76 tRNA processing -1.11069 0.00552 
101.  TBC1D8B regulation of Rab GTPase activity -1.11681 0.006732 
102.  TET3 oxidation-reduction process -1.11892 0.002769 
103.  HIBCH branched chain family amino acid catabolic process  -1.1232 0.000546 
104.  C5 activation of MAPK activity g pathway -1.12359 0.000257 
105.  PRPF4B nuclear mRNA splicing, via spliceosome  -1.13006 0.004421 
106.  HMGB3 DNA recombination  -1.13404 0.001608 
107.  CASP1 apoptosis  -1.1451 0.003074 
108.  ARHGAP5 cell adhesion  -1.14673 0.006035 
109.  RIC8B regulation of G-protein coupled receptor protein  -1.14797 0.002709 
110.  TIA1 apoptosis  -1.14852 0.001733 
111.  B3GNT6 protein glycosylation  -1.16122 0.008494 
112.  LYG1 metabolic process / peptidoglycan catabolic process  -1.18663 0.001265 
113.  LUC7L3 apoptosis / mRNA processing -1.21856 0.003643 
114.  ZRANB2 transcription, DNA-dependent / mRNA processing  -1.22432 0.003998 
115.  TAF9B transcription initiation, DNA-dependent  -1.23045 0.000572 
116.  FMN1 actin cytoskeleton organization  -1.24468 0.008358 
117.  ZNF148 negative regulation of transcription  -1.24485 0.000852 
118.  L3MBTL1 regulation of cell cycle  -1.24825 0.003229 
119.  HERC4 protein ubiquitination  -1.27386 0.002253 
120.  N4BP2L2 cell killing / biological_process -1.30173 0.001487 
121.  TFRC response to hypoxia -1.33116 0.003532 
122.  CCDC41 biological_process -1.34177 0.003825 
123.  SSR1 cotranslational protein targeting to membrane  -1.38737 0.00834 
124.  OMA1 proteolysis -1.40119 0.000229 
125.  IFNAR1 JAK-STAT cascade  -1.4955 0.001177 
126.  HS3ST3B1 heparan sulfate proteoglycan biosynthetic process  -1.51249 0.008323 
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127.  MTERFD3 regulation of transcription -1.64193 0.008759 
128.  PREPL proteolysis -1.66411 0.001247 
129.  EIF4A2 nuclear-transcribed mRNA catabolic process -1.76099 9.18E-05 
130.  HIST1H2AC nucleosome assembly -1.8072 0.006223 
131.  GLIS3 regulation of transcription     -1.9221  0.004129 
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Supplementary Table IV. List of the top functions associated with networks modulated by 
hypoxia in human APCs. 
ID Score Focus Genes Top Functions 
1 50 28 Cell Cycle 
2 47 28 Carbohydrate Metabolism 
3 29 19 Cell Death/apoptosis and cell-to-cell signalling/interaction  
LEP is the central core of Network 3. Score = Total genes in network; Focus Genes = Genes regulated in dataset. 
Details of the 19 genes modulated network 3 are given in Supplementary Table V. 
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Supplementary Table V. List of genes comprised in the network 3 identified by IPA 
Symbol Full Name Aliases 
AANT Aralkylamine N Acetyltransferase DSPS, SNAT, AANAT 
ACSL3 AcylCoA Synthetase Long Chain Family Member 3 ACS3, PRO2194, FACL3, LACS3 
CASP1 Caspase 1, Apoptosis Related Cysteine Peptidase p45, caspase1, beta, convertase, 
IL1B convertase, IL1BC, ICE, 
CASP1, IL1BC, IL1BCE 
CTSL1 Cathepsin L1  EC 3.4.22.15, MEP, CATL 
 
CXCL2 Chemokine (CXC Motif) Ligand 2 
 
MIP2A, MIP2A, MIP2, CINC2a, 
GROb, MGSAb, grobeta, GRO2, 
MIP2alpha, SCYB2 
HS3ST3B1 Heparan Sulfate (Glucosamine) 3O Sulfotransferase 
3B1 
3OST3B, 3OST3B1,h3OST3B, 
30ST3B1, HS3ST3B 
IRGM Immunity Related GTPase Family, M IRGM1, IFI1, LRG47, LRG47, 
IBD19 
IVNS1ABP Influenza Virus NS1A Binding Protein ND1, NS1, HSPC068, KLHL39, 
NS1, NS1BP, FLARA3, 
KIF20A Kinesin Family Member 20A rabkinesin6, RAB6KIFL, 
GG10_2, MKLP2 
LEP Leptin OB, leptin, OBS, LEPD 
MARK4 MAP/Microtubule Affinity Regulating Kinase 4 MARK4L, MARK4S, MARKL1L, 
NME7 NME/NM23 Family Member 7 CFAP67, NDK7, MN23H7, 
nm23H7 
PLA2G4C Phospholipase A2, Group IVC (Cytosolic, Calcium 
Independent) 
CPLA2gamma 
SERPINH1 Serpin Peptidase Inhibitor, Clade H (Heat Shock 
Protein 47), Member 1, (Collagen Binding Protein1) 
PIG14, RAA47, colligin1, 
colligin2, gp46, OI10, PPROM, 
CBP1, CBP2, SERPINH2, AsTP3, 
HSP47, Colligin 
TREM1 Triggering Receptor Expressed On Myeloid Cells 1 CD354, TREM1 
VEGFA Vascular Endothelial Growth Factor A MVCD1, VEGF, VPF, VEGFA 
WIPF1 WAS/WASL Interacting Protein Family, Member 1 PRPL2, WAS2, WASPIP, WIP 
ZEB1 Zinc Finger EBox Binding Homeobox 1 BZP, DELTAEF1, ZFHEP, 
ZFHX1A, FECD6, NIL2A, PPCD3, 
TCF8, AREB6, TCF8 
ZRANB2 Zinc Finger, RAN Binding Domain Containing 2 ZIS1, ZIS2, ZNF265, ZIS 
Upregulated (red) and downregulated genes (green)  
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Supplementary Table VI. Primers and probes used to assess gene expression by qPCR 
Target 
gene 
Commercial information qPCR assay 
Nomenclature/ 
Function 
LEP 
QT000030261 (QIAGEN); 
Hs00174877 (Applied 
Biosystems) 
SYBR Green; 
Taqman 
Leptin 
LEPR 
QT00006524 (QIAGEN); 
Hs00174497 (Applied 
Biosystems) 
SYBR Green ; 
Taqman 
Leptin receptor 
18S QT001969367 (QIAGEN) SYBR Green 
Housekeeping genes 
UBC 
Hs1871556 (Applied 
Biosystems) 
Taqman 
MIR210 00512 (Applied Biosystems) Taqman hsa-miR-210-3p 
snRNAU6 001973 (Applied Biosystems) Taqman miRNA housekeeping 
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Supplementary Table VII. Catalogue numbers of antibodies used 
Target 
protein 
 Assay Catalogue 
number 
Supplier 
PDGFRβ  IF sc-339 Santa Cruz 
NG2  IF AB5320 Millipore 
GATA-4  IF ab61767 Abcam 
Isolectin B4  IF I21414 Invitrogen 
α-SMA  IF C6198 Sigma-Aldrich 
Alexafluor48
8 Anti-Rabbit 
 IF A-11008 Invitrogen 
Alexafluor48
8 Anti-mouse 
 IF A-11001 Invitrogen 
p-STAT3 
(tyr705) 
 Western blot 9145 (D3A7) Cell Signalling 
Total STAT3  Western blot 9139 (124H6) Cell Signalling 
p-AKT  Western blot 9271 Cell Signalling 
Total AKT  Western blot 9272 Cell Signalling 
p-ERK1/2 
(Thr 
202/204) 
 Western blot 9101 Cell Signalling 
Total ERK1/2  Western blot 4695 (137F5) Cell Signalling 
PTP1B  Western blot 5311 Cell Signalling 
β-actin  Western blot A5441 (AC15) Sigma Aldrich 
Leptin 
receptor 
 Western blot ab104403 abcam 
Anti-Rabbit 
IgG 
 Western blot NA934 GE Healthcare 
Anti-mouse 
IgG 
 Western blot NA931 Ge healthcare 
CD105  FACS MHCD10505 Life technologies 
CD90  FACS 328124 Biolegend 
CD73  FACS 344010 Biolegend 
PDGFRβ  FACS 323606 Biolegend 
CD44  FACS 17-0441-82 eBiosciences 
CD31  FACS 555445 BD Biosciences 
CD34  FACS 130-081-001 Miltenyi 
CD45  FACS 130-094-975 Miltenyi 
NG2   FACS 8012-6504-120 eBioscience 
NG2  Cell sorting 130-097-171 Miltenyi 
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Supplementary Figure I: APCs morphology (a, contrast phase microscopy) and 
immunocytochemistry images of typical APC antigens captured 40x (b). Typical histograms of 
flow cytometry data from a representative cell line under normoxia (c) and hypoxia (d).  Average 
values of markers expression (e). Individual and average data of four cell lines are also shown in 
Supplementary Table II. Expression of these typical markers is similar in APCs exposed to 
normoxia or hypoxia.  
 
 
 
  
a  b  
c  d  
e  
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Supplementary Figure II: Ingenuity® Pathway Analysis (IPA) of genes modulated by hypoxia in 
human APCs, based on two metrics: z-score and p-value. A positive or negative z-score value 
indicates that a function is increased or decreased in hypoxic relative to normoxic cells. In order 
to enhance the stringency of the analysis, we considered only functions with a z-score > 1 or < -1. 
The p-value (red dots), calculated with the Fischer's exact test, reflects the likelihood that the 
association between a set of genes in the dataset and a related biological function is significant. 
Results indicate that LEP is implicated in the majority of functions modulated by hypoxia. 
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Supplementary Figure III: Effect of miR-210 inhibition on LEP mRNA and LEP protein 
expression and signalling. Experiments were conducted on four cell lines. (a) Bar graph shows 
validation of effective miR-210 inhibition by the antago-miR. (b-d) Hypoxia-induced upregulation 
of LEP mRNA and LEP protein levels is not affected by miR-210 inhibition (n=4, ***p<0.001 vs. 
scramble and vehicle, ##p<0.01 vs. normoxia. (e) Bar graph showing unchanged expression of 
PTP1B protein under normoxia and hypoxia (n=4, p=N.S. vs. normoxia. (f) Inhibition of miR-210 
upregulates the expression of the target PTP1B protein (n=7, *p<0.05 vs. Scramble).  (g) ELISA 
showed no change in phosphorylated JAK2 levels in response to miR-210 inhibition (n=7, p=N.S. 
vs. Scramble). 
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Supplementary Figure IV:  Validation of LEP and LEPR silencing by siRNA. (a) Effective silencing 
of LEP by siRNA ***p<0.001 vs. scramble sequence. (b) Hypoxia induces increased leptin 
secretion, which is inhibited by LEP siRNA. *p<0.05 and ***p<0.001 vs. normoxia and scramble 
sequence, respectively. (c and d) Effective LEPR silencing in APCs (c, Bar graph shows the average 
of four biological replicates. ***p<0.001 vs. scramble) and HUVECs (d, ***p<0.001 vs. scramble). 
Inserts illustrate representative Western blots of the LEPR protein in APCs and HUVECs 
transfected with siLEPR or scramble. 
 
 
  
c  d  
a  b  
17 
 
 
Supplementary Figure V: Original full western blot images displayed in this manuscript 
and additional information regarding with the immunoblots of phosphorylated and total 
proteins (Panels 1-6) 
Experiments were performed in different APC lines (n ≥ 3) for each control and experimental 
condition. All experimental conditions were compared with each respective control condition in 
the same gel. Antibodies used in this manuscript have been previously used in our laboratory as 
published previously.1-3 Different titration was performed for the antibodies during the protocol 
optimization. All PVDF membranes were assessed for the loading control (-actin or occasionally 
/-tubulin) to confirm that different protein levels were not a result of pipetting error. Membranes 
were incubated up to 10 min with the ECL prime reagent (GE Healthcare) according to 
manufacturer’s instructions. Only the best and representative images were captured for 
publication. Image capture was usually performed using ChemiDoc MP system (Bio-Rad) or by 
Li-cor image 700/800 wavelength (Biosciences). Original Western blotting images were 
digitalized at 600 dpi by using Image Lab 5.1 software (Bio-Rad). Band densitometry was 
performed by Image J online software for all bands including targets and loading controls. Ratios 
among the area calculated for the target and the area calculated for the loading control were 
assessed in each sample to calculate the relative area of the protein of interest. The area of the 
control condition was considered 1 and the fold change was calculated for the targeted protein. 
Using fold change values, we compared the regulatory effect of the experimental condition vs. its 
respective control condition for each APC line at the protein level. After demonstrating no 
regulation of the selected loading control by the experimental conditions, new gels were often 
run to achieve representative and improved images for each sample which are included in the 
final version of this manuscript. Brightness processing were performed if necessary and always 
applied equally to control and experimental samples. No further improving image procedures 
were performed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
Panel 1 (refer to text Figure 2e. Hypoxia induces leptin production and secretion by human 
APCs). Representative original immunoblots performed in a single membrane to confirm LEPR 
regulation in hypoxic APCs. Bands displayed in this manuscript has been framed into red boxes.  
 
 
Panel 2 (refer to text Figure 3a. Effect of exogenous rh-leptin on canonical signalling and 
functional assays in human APCs.). Original images captured using Licor image 700/800 
wavelength. Images i and ii correspond to Li-cor imaging; Image iii corresponds to the grey-scale 
image for image i; Image iv corresponds to the grey-scale image for image ii. Bands displayed in 
this manuscript has been framed into red boxes.  
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Panel 3 (refer to text Figure 4a. Effect of normoxia and hypoxia on LEP-associated kinases 
and functional activities of human APCs). Sequential immunoblots performed in a single 
membrane are indicated in ordinal numbers starting from ‘1st’. Bands displayed in this 
manuscript has been framed into red boxes.  
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Panel 4 (refer to text Figure 4b. Effect of LEP silencing on LEP-associated kinases and 
functional activities of human APCs). Sequential immunoblots performed in a single 
membrane are indicated in ordinal numbers starting from ‘1st’. Bands displayed in this 
manuscript has been framed into red boxes.  
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Panel 5 (refer to text Figure 4c. Effect of LEPR silencing on LEP-associated kinases and 
functional activities of human APCs). Sequential immunoblots performed in a single 
membrane are showed. Bands displayed in this manuscript has been framed into red boxes. 
 
Panel 6 (refer to Supplementary Figure III e. Effect of normoxia and hypoxia on PTP1B 
protein expression.). Sequential immunoblots (if any) performed in a single membrane are 
indicated in ordinal numbers starting from ‘1st’. Bands displayed in this manuscript has been 
framed into red boxes.  
 
 
 
 
 
 
 
 
Panel 7 (refer to Supplementary Figure III f. Effect of miR-210 inhibition PTP1B protein 
expression). Sequential immunoblots (if any) performed in a single membrane are indicated in 
ordinal numbers starting from ‘1st’. Bands displayed in this manuscript has been framed into red 
boxes.  
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Panel 8 (refer to Supplementary Figure IV c. Validation of LEP and LEPR silencing by 
siRNA). Sequential immunoblots performed in a single membrane are showed. LEPR silencing in 
APCs exposed to hypoxia was evidenced by western blot. Bands displayed in this manuscript has 
been framed into red boxes. 
 
Panel 9 (refer to Supplementary Figure IV d. Validation of LEP and LEPR silencing by 
siRNA). Sequential immunoblots performed in a single membrane are showed. LEPR silencing in 
HUVECs exposed to normoxia was evidenced by western blot. Bands displayed in this manuscript 
has been framed into red boxes. 
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